GlassScriptPhysician profile
Basil C Hamblin
NPI 1114095106
$3,133.71
in general payments reported to CMS, 2019-2025
30 companies · $378 in 2025
The $378 reported for 2025 was more than what 77% of Geriatric Medicine (Family Medicine) providers received nationally (typical 2025 total: $119).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $643 · 2020: $216 · 2021: $428 · 2022: $393 · 2023: $492 · 2024: $584 · 2025: $378.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,437 · Education: $17.44.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,437.16 |
| Education | $17.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Collegium Pharmaceutical, INC. | $542.53 | 2019-2025 | Belbuca, Xtampza |
| Novo Nordisk INC | $360.19 | 2019-2024 | Rybelsus, Ozempic |
| Indivior INC. | $309.28 | 2019-2024 | Sublocade |
| Sunovion Pharmaceuticals INC. | $278.34 | 2019-2022 | |
| Astellas Pharma US INC | $178.62 | 2019-2024 | Veozah, Myrbetriq |
| Pfizer INC. | $124.69 | 2023-2025 | |
| Kyowa Kirin, INC. | $117.37 | 2023-2025 | Crysvita |
| Ucb, INC. | $116.54 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $115.71 | 2019 | |
| Nestle Healthcare Nutrition INC. | $87.31 | 2021 | |
| Janssen Pharmaceuticals, INC | $83.43 | 2019-2021 | |
| Braeburn INC. | $80.89 | 2024 | Brixadi |
| Sanofi Pasteur INC. | $78.22 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $77.36 | 2024-2025 | Farxiga, Lokelma |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $71.20 | 2019-2025 | Xifaxan |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $70.42 | 2023-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $55.39 | 2019-2024 | Pifeltro, Dificid |
| Otsuka America Pharmaceutical, INC. | $53.75 | 2024 | Nuedexta |
| Mimedx Group, INC. | $48.66 | 2024 | |
| Argenx US, INC. | $48.11 | 2025 | Vyvgart, Vyvgart Hytrulo |
| Neurocrine Biosciences, INC. | $46.47 | 2025 | |
| Eisai INC. | $36.58 | 2022 | |
| Insmed, INC. | $32.44 | 2025 | Arikayce |
| Sumitomo Pharma America, INC. | $23.00 | 2023 | Latuda |
| Glaxosmithkline, LLC. | $20.54 | 2023 | Shingrix, Arexvy |
| Acadia Pharmaceuticals INC | $19.58 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $18.31 | 2024 | Uzedy |
| Biogen, INC. | $14.53 | 2021 | |
| Gilead Sciences, INC. | $12.18 | 2019 | |
| Circassia INC. | $12.07 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Basil Hamblin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.